Evidence map›Paper›PMID 39957239›Full record

ReviewTherapeutic delivery2025

Exosomes in glioma: mechanistic insights on biological, therapeutic, and diagnostic perspective.

Reetika Tandon, Samarth Kumar, Mayank Handa, Nidhi Srivastava

Abstract readReview
In one paragraph

Review in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Reetika TandonDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.
Samarth KumarFormulation Research & Development-Non Orals, Sun Pharmaceuticals Industries Limited, Vadodara, India.
Mayank HandaFormulation Research & Development-Non Orals, Sun Pharmaceuticals Industries Limited, Vadodara, India.
Nidhi SrivastavaDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are prominent and frequent primary malignant brain tumors, with a generally poor prognosis. Current treatment involves radiation, surgery and chemotherapy. Exosomes are nanoscale extracellular vesicles released by cells that enable biological molecule movement and encourage intercellular communication in the tumor microenvironment. This contributes to glioma development, radiation resistance, and overcomes chemotherapy. Exosome functional and structural properties are essential for understanding cancer molecular mechanisms. They can also treat invasive tumors like glioblastomas and serve as diagnostic markers. Recent research depicted exosomes' prominent role in cancer cell maintenance, intercellular signaling, and microenvironment modification. Exosomes hold nucleic acids, proteins, lipids, mRNAs, lncRNAs, miRNAs, and immunological regulatory molecules depending on the origin of the cell. This paper reviews exosomes, their role in glioma etiology, and perspective diagnostic and therapeutic uses.

Indexed as

Brain NeoplasmsExosomesGliomaAnimalsBiomarkers, TumorCell CommunicationHumansTumor MicroenvironmentBiomarkers, Tumorblood-brain barriercell signalingGlioblastomaRNAstheranostic

Identifiers

PMID39957239
PMCPMC12135692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.